ATODEL

This brand name is authorized in Cyprus, Malta, Singapore

Active ingredients

The drug ATODEL contains one active pharmaceutical ingredient (API):

1 Prazosin UNII XM03YJ541D - PRAZOSIN

Prazosin causes a decrease in total peripheral vascular resistance through selective inhibition of postsynaptic alpha-1-adrenoreceptors in vascular smooth muscle. Prazosin has been found to successfully reduce the severity of the signs, symptoms, frequency and duration of attacks, in patients with Raynaud’s disease. Read about Prazosin

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
ATODEL Tablet	Υπουργείο Υγείας (CY)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
C02CA01	Prazosin	C Cardiovascular system → C02 Antihypertensives → C02C Antiadrenergic agents, peripherally acting → C02CA Alpha-adrenoreceptor antagonists
Discover more medicines within C02CA01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: MT	Medicines Authority	Identifier(s): AA084/11101
Country: SG	Health Sciences Authority	Identifier(s): 06018P, 07529P